Zenas BioPharma Inc. (ZBIO)
6.60
-0.41 (-5.85%)
At close: Mar 03, 2025, 3:59 PM
6.26
-5.15%
After-hours: Mar 03, 2025, 05:53 PM EST
No 1D chart data available
| Bid | 6.15 |
| Market Cap | 275.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -2.14 |
| Forward PE | -1.76 |
| Analyst | Buy |
| Ask | 7.8 |
| Volume | 113,760 |
| Avg. Volume (20D) | 296,803 |
| Open | 6.98 |
| Previous Close | 7.01 |
| Day's Range | 6.60 - 7.04 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | -3.38 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclo...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ZBIO
Website https://zenasbio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ZBIO stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 354.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
